Education
About Us
Working with TipRanks
Follow Us
Pliant Therapeutics (PLRX)
NASDAQ:PLRX
PLRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.26 - $16.52
Previous CloseN/A
Volume34.91K
Average Volume (3M)3.17M
Market Cap
$90.02M
Enterprise Value$336.49M
Total Cash (Recent Filing)-$4.25M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.47
Next Earnings
May 12, 2025EPS Estimate
-0.77Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.47
Shares Outstanding61,236,290
10 Day Avg. Volume2,076,936
30 Day Avg. Volume3,165,566
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)52.32
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap3.74
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.64
Forecast
1Y Price Target
$5.25Price Target Upside257.14% Upside
Rating ConsensusHold
Number of Analyst Covering13
---
Bulls Say, Bears Say
Bulls Say
Drug EfficacyPLN-101095 showed a partial response rate of 50% at the highest dose cohort.
Oncology Program AdvancementsThe oncology program is advancing with an ongoing open-label, dose-escalation study for PLN-101095 in solid tumors, with interim results expected in the first quarter of 2025.
Bears Say
Clinical Program UncertaintyThe discontinuation of the IPF clinical program for bexotegrast was due to a higher rate of adverse events in the treatment group compared to the placebo group.
Clinical Trial DiscontinuationPLRX announced discontinuation of the BEACON-IPF study due to an imbalance in adverse events in the active vs placebo groups.
Safety ConcernsThere was one dose-limiting toxicity of autoimmune hepatitis at 1000mg as well as skin toxicities.
---
Ownership Overview
4.40% Insiders
19.84% Mutual Funds
0.50% Other Institutional Investors
63.51% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PLRX FAQ
What was Pliant Therapeutics’s price range in the past 12 months?
Pliant Therapeutics lowest stock price was $1.26 and its highest was $16.52 in the past 12 months.
What is Pliant Therapeutics’s market cap?
Pliant Therapeutics’s market cap is $90.02M.
When is Pliant Therapeutics’s upcoming earnings report date?
Pliant Therapeutics’s upcoming earnings report date is May 12, 2025 which is in 40 days.
How were Pliant Therapeutics’s earnings last quarter?
Pliant Therapeutics released its earnings results on Mar 03, 2025. The company reported -$0.82 earnings per share for the quarter, beating the consensus estimate of -$0.956 by $0.136.
Is Pliant Therapeutics overvalued?
According to Wall Street analysts Pliant Therapeutics’s price is currently Undervalued.
Does Pliant Therapeutics pay dividends?
Pliant Therapeutics does not currently pay dividends.
What is Pliant Therapeutics’s EPS estimate?
Pliant Therapeutics’s EPS estimate is -0.77.
How many shares outstanding does Pliant Therapeutics have?
Pliant Therapeutics has 61,236,290 shares outstanding.
What happened to Pliant Therapeutics’s price movement after its last earnings report?
Pliant Therapeutics reported an EPS of -$0.82 in its last earnings report, beating expectations of -$0.956. Following the earnings report the stock price went down -2.174%.
Which hedge fund is a major shareholder of Pliant Therapeutics?
Currently, no hedge funds are holding shares in PLRX
---
Pliant Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$5.25 (257.14% Upside)
$5.25 (257.14% Upside)
Blogger Sentiment
Bullish
PLRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 45.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 1.2%
Last 30 Days ▲ 1.8%
Last 30 Days ▲ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-90.13%
12-Months-Change
Fundamentals
Return on Equity
-54.09%
Trailing 12-Months
Asset Growth
-22.49%
Trailing 12-Months
Company Description
Pliant Therapeutics
Pliant Therapeutics (PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrotic diseases. The company operates in the biotechnology and pharmaceuticals sector, leveraging its proprietary platform to identify and advance small molecule therapeutics targeting key pathways in fibrosis, a process implicated in a wide array of serious diseases. Pliant's core products are centered on treating diseases like idiopathic pulmonary fibrosis and primary sclerosing cholangitis.
---
PLRX Stock 12 Month Forecast
Average Price Target
$5.25
▲(257.14% Upside)
Technical Analysis
Arrowhead Pharmaceuticals
―
Nektar Therapeutics
―
Vertex Pharmaceuticals
―
Blueprint Medicines
―
Galapagos
―
Best Analysts Covering PLRX
1 Year
1 Year Success Rate
3/16 ratings generated profit
1 Year Average Return
-21.63%
reiterated a buy rating last month
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 18.75% of your transactions generating a profit, with an average return of -21.63% per trade.
---